vs

Side-by-side financial comparison of MYERS INDUSTRIES INC (MYE) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

MYERS INDUSTRIES INC is the larger business by last-quarter revenue ($204.0M vs $37.2M, roughly 5.5× Organogenesis Holdings Inc.). On growth, MYERS INDUSTRIES INC posted the faster year-over-year revenue change (0.0% vs -57.1%). Over the past eight quarters, MYERS INDUSTRIES INC's revenue compounded faster (-0.8% CAGR vs -46.5%).

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid ...

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

MYE vs ORGO — Head-to-Head

Bigger by revenue
MYE
MYE
5.5× larger
MYE
$204.0M
$37.2M
ORGO
Growing faster (revenue YoY)
MYE
MYE
+57.1% gap
MYE
0.0%
-57.1%
ORGO
Faster 2-yr revenue CAGR
MYE
MYE
Annualised
MYE
-0.8%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MYE
MYE
ORGO
ORGO
Revenue
$204.0M
$37.2M
Net Profit
$11.3M
Gross Margin
33.2%
30.8%
Operating Margin
9.9%
-185.1%
Net Margin
5.6%
Revenue YoY
0.0%
-57.1%
Net Profit YoY
163.7%
EPS (diluted)
$0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MYE
MYE
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$204.0M
$225.6M
Q3 25
$205.4M
$150.9M
Q2 25
$209.6M
$101.0M
Q1 25
$206.8M
$86.7M
Q4 24
$203.9M
$126.7M
Q3 24
$205.1M
$115.2M
Q2 24
$220.2M
$130.2M
Net Profit
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
$11.3M
$43.7M
Q3 25
$7.1M
$21.6M
Q2 25
$9.7M
$-9.4M
Q1 25
$6.8M
$-18.8M
Q4 24
$4.3M
$7.7M
Q3 24
$-10.9M
$12.3M
Q2 24
$10.3M
$-17.0M
Gross Margin
MYE
MYE
ORGO
ORGO
Q1 26
30.8%
Q4 25
33.2%
Q3 25
33.4%
Q2 25
33.7%
Q1 25
33.4%
72.6%
Q4 24
32.3%
75.5%
Q3 24
31.8%
76.7%
Q2 24
34.3%
77.6%
Operating Margin
MYE
MYE
ORGO
ORGO
Q1 26
-185.1%
Q4 25
9.9%
28.1%
Q3 25
8.6%
13.7%
Q2 25
9.5%
-12.5%
Q1 25
8.1%
-30.9%
Q4 24
7.2%
8.1%
Q3 24
-2.3%
5.4%
Q2 24
10.8%
-10.7%
Net Margin
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
5.6%
19.4%
Q3 25
3.5%
14.3%
Q2 25
4.6%
-9.3%
Q1 25
3.3%
-21.7%
Q4 24
2.1%
6.1%
Q3 24
-5.3%
10.7%
Q2 24
4.7%
-13.1%
EPS (diluted)
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
$0.30
$0.31
Q3 25
$0.19
$0.11
Q2 25
$0.26
$-0.10
Q1 25
$0.18
$-0.17
Q4 24
$0.11
$0.05
Q3 24
$-0.29
$0.09
Q2 24
$0.28
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MYE
MYE
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$45.0M
$91.4M
Total DebtLower is stronger
$345.8M
Stockholders' EquityBook value
$294.2M
Total Assets
$851.3M
$520.0M
Debt / EquityLower = less leverage
1.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MYE
MYE
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$45.0M
$93.7M
Q3 25
$48.0M
$63.7M
Q2 25
$41.3M
$73.1M
Q1 25
$35.3M
$110.0M
Q4 24
$32.2M
$135.6M
Q3 24
$29.7M
$94.3M
Q2 24
$37.3M
$89.9M
Total Debt
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
$345.8M
Q3 25
$361.2M
Q2 25
$370.8M
Q1 25
$383.4M
Q4 24
$375.0M
Q3 24
$387.5M
$62.3M
Q2 24
$400.1M
$63.8M
Stockholders' Equity
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
$294.2M
$300.1M
Q3 25
$286.6M
$255.1M
Q2 25
$284.6M
$233.2M
Q1 25
$277.4M
$242.9M
Q4 24
$277.5M
$262.9M
Q3 24
$275.6M
$278.5M
Q2 24
$294.6M
$263.5M
Total Assets
MYE
MYE
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$851.3M
$598.7M
Q3 25
$864.1M
$509.8M
Q2 25
$862.7M
$461.1M
Q1 25
$883.8M
$467.4M
Q4 24
$860.8M
$497.9M
Q3 24
$905.0M
$446.3M
Q2 24
$951.6M
$443.2M
Debt / Equity
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
1.18×
Q3 25
1.26×
Q2 25
1.30×
Q1 25
1.38×
Q4 24
1.35×
Q3 24
1.41×
0.22×
Q2 24
1.36×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MYE
MYE
ORGO
ORGO
Operating Cash FlowLast quarter
$22.6M
Free Cash FlowOCF − Capex
$18.9M
FCF MarginFCF / Revenue
9.3%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
1.99×
TTM Free Cash FlowTrailing 4 quarters
$67.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
$22.6M
$39.4M
Q3 25
$25.8M
$3.1M
Q2 25
$28.3M
$-32.9M
Q1 25
$10.1M
$-19.9M
Q4 24
$27.3M
$10.9M
Q3 24
$17.3M
$8.7M
Q2 24
$14.3M
$4.7M
Free Cash Flow
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
$18.9M
$34.8M
Q3 25
$21.5M
$844.0K
Q2 25
$24.7M
$-36.5M
Q1 25
$2.0M
$-23.6M
Q4 24
$20.2M
$7.6M
Q3 24
$10.1M
$6.1M
Q2 24
$9.9M
$2.9M
FCF Margin
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
9.3%
15.4%
Q3 25
10.5%
0.6%
Q2 25
11.8%
-36.1%
Q1 25
1.0%
-27.2%
Q4 24
9.9%
6.0%
Q3 24
4.9%
5.3%
Q2 24
4.5%
2.2%
Capex Intensity
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
1.8%
2.1%
Q3 25
2.1%
1.5%
Q2 25
1.7%
3.6%
Q1 25
3.9%
4.2%
Q4 24
3.5%
2.7%
Q3 24
3.5%
2.2%
Q2 24
2.0%
1.4%
Cash Conversion
MYE
MYE
ORGO
ORGO
Q1 26
Q4 25
1.99×
0.90×
Q3 25
3.63×
0.14×
Q2 25
2.92×
Q1 25
1.49×
Q4 24
6.36×
1.43×
Q3 24
0.71×
Q2 24
1.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MYE
MYE

Industrial$64.3M32%
Auto Aftermarket$51.7M25%
Infrastructure$34.0M17%
Food And Beverage$23.2M11%
Vehicle$17.9M9%
Consumer$12.9M6%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons